BP102 clinical trials
A product of Bevacizumab; its studies count on that page too.
How each study uses BP102 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the BP102 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 26 Feb 2004 · AVASTIN · BLA 125085 (FDA, Drugs@FDA; as Bevacizumab)
- European Union
- 12 Jan 2005 · Avastin · EMEA/H/C/000582 (EMA; as Bevacizumab)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
7 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 2
Jiangsu HengRui Medicine Co., Ltd. (2) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (2) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Fudan University (1) · Shandong Suncadia Medicine Co., Ltd. (1)
Often tested with
Tested in the same studies.
Adebrelimab (2) · Trastuzumab rezetecan (1) · Camrelizumab (1) · Famitinib (1) · Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 (1) · Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 (1) · FH-006 (1) · Anti-CTLA-4 Monoclonal Antibody SHR-8068 (1)
Related medicines
As reviewed, each with the page that says it.
- A biosimilar of Bevacizumab
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test BP102.
- Dec 2026A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant TumourPhase 2 · Shandong Suncadia Medicine Co., Ltd.
- Nov 2027A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung CancerPhase 2 · Jiangsu HengRui Medicine Co., Ltd.
Studies
Open first, then newest update. How each study uses BP102 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- FUSCC Refractory TNBC Platform Study (FUTURE2.0)RecruitingPhase 2Fudan UniversityNCT05749588Written as C2: SHR-A1811 with BP102
- A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung CancerRecruitingPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT07241767Written as FH-006 ; SHR-1316 ; BP102 ; Cisplatin ; Carboplatin
- A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant TumourRecruitingPhase 2Shandong Suncadia Medicine Co., Ltd.NCT06915142Written as HRS-7058 + BP102
- Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory GlioblastomaCompletedPhase 1Second Affiliated Hospital, Zhejiang University, School of MedicineNCT04385173Written as BP102 (B7-H3 CAR-T)
- A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRCTerminatedPhase 2/3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT04856787Written as SHR-1701、 BP102 、XELOX
- A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical CancerTerminatedPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT05179239Written as SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102
- To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLCCompletedPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT05169801Written as BP102, paclitaxel, carboplatin
Given beside what is tested · 7 — BP102 is usual care or a partner of the new treatment
- A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid TumorsRecruitingPhase 2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT07268040Written as BP102 Injection
- An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal CancerNot yet recruitingPhase 2Fudan UniversityNCT07061210Written as BP102
- A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLCRecruitingPhase 1/2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06754930Written as BP-102
- SHR-1701 Combined with SHR2554 and BP102 for MCRCNot yet recruitingPhase 2Fudan UniversityNCT06679673Written as BP102
- SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal CancerNot yet recruitingPhase 1/2West China HospitalNCT06373133Written as BP102
- A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLCTerminatedPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT03666728Written as BP102
- SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal CancerTerminatedPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT03645876Written as BP102